Navigation Links
Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
Date:8/14/2008

FAIRFIELD, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused on oncology, today announced the appointment of Brian Lenz, CPA, as its Chief Financial Officer. Mr. Lenz brings over 10 years of financial and operational management experience in addition to significant experience in capital raising and M&A activities.

"We are very pleased to have someone with Brian's broad financial and public markets experience join our team," said Scott Z. Fields, MD, President and Chief Medical Officer of Arno. "We look forward to working with him as we continue to grow and expand our operations."

Prior to joining Arno Therapeutics, Mr. Lenz was Chief Financial Officer and Treasurer of VioQuest Pharmaceuticals, Inc. since 2004, and prior to that served as the company's controller from 2003 to 2004. At VioQuest, Mr. Lenz was responsible for the financial and operational reporting, as well as capital raising and M&A activities. Prior to VioQuest, Mr. Lenz was a controller with Smiths Detection Group from 2000 to 2003. Before joining Smiths, Mr. Lenz was a senior auditor with KPMG, LLP from 1998 to 2000. Mr. Lenz holds a BS in Accounting from Rider University and received his MBA from Saint Joseph's University. He is a certified public accountant licensed in the State of New Jersey.

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead compound is AR-67, a novel, third-generation camptothecin analogue in Phase I studies in patients with advanced solid tumors that has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available PDK
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
5. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
6. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
7. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
8. CV Therapeutics Reports 2008 Second Quarter Financial Results
9. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
10. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
11. Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 Quincy Bioscience, ... and development of calcium-binding proteins to support healthy ... safety assessment study of apoaequorin in ... published for the British Industrial Biological Research Association. ... to investigate potential adverse effects, if any, of ...
(Date:5/23/2013)... 23, 2013 Venaxis, Inc. (Nasdaq:   APPY), ... obtaining FDA clearance and commercializing its rapid, protein biomarker-based ... of an underwritten public offering of 10,000,000 shares of ... shares of its common stock at an exercise price ... price of $1.25 per share and related warrant.  Venaxis ...
(Date:5/23/2013)... May 23, 2013 Graphite Metallizing ... self-lubricating bushings mounted in stainless steel pillow blocks. ... of GRAPHALLOY with the application and installation versatility ... Pillow Blocks work exceptionally well when submerged ... hostile liquids such as acids, alkalies, hydrocarbons, black ...
(Date:5/23/2013)... Ind. , May 23, 2013  Rahal Letterman ... in human cord blood stem cell banking and therapeutics, ... of the No. 16 Acorn Stairlifts Indy car driven ... for the remainder of the IZOD IndyCar 2013 season. ... (RLL) will work to support awareness of umbilical cord ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3
... by leading international cardiology societiesTOKYO and INDIANAPOLIS, May ... 38 study applied the new classification system for ... results of the study and showed that patients ... intervention (PCI) and taking prasugrel, as compared with ...
... ,Agendia, a world leader in molecular cancer diagnostics, today ... California San Francisco ,and the Netherlands Cancer Institute will ... Clinical Oncology Annual Meeting, May 29 - June 2,2009, ... study results further underpin the broad predictive and prognostic,power ...
... VIENNA, Austria, May 21 EUCODIS Bioscience, a ... for the,chemical industry, announced today that it has ... of Danisco. Under the terms of the,agreement, EUCODIS ... vivo recombination" to the development of an optimized,version ...
Cached Biology Technology:Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 2Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 3Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 4Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 5Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 6Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting 2Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting 3EUCODIS Bioscience Signs Research Agreement With Genencor 2
(Date:5/23/2013)... Investigators at Rollins School of Public Health at ... Institute of Technology, have received a $4 million ... Center at Emory University (Health and Exposome Research ... first exposome-based center grant awarded in the United ... by the National Institute of Environmental Health Sciences ...
(Date:5/23/2013)... (May 23, 2013) A new report from the ... helping pupils engage in at least 60 minutes of ... , No more than half of American youth meet ... vigorous or moderate intensity physical activity daily, according to ... children are in school for nearly half of their ...
(Date:5/23/2013)... an age when microbial pathogens are growing increasingly resistant ... a team of Wisconsin scientists has synthesized a potent ... that cause staph infections. , Writing online in the ... group led by University of Wisconsin-Madison chemistry Professor Helen ... sensing" behavior of Staphylococcus aureus , a bacterium ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide students with daily physical activity, IOM recommends 2University of Wisconsin chemists find new compounds to curb staph infection 2
... South African scientists working at the epicenter of the ... human immunodeficiency virus (HIV) "exhausts" killer T cells that ... HIV can simply "turn off" fully functional T cells ... test tube studies, however, the scientists showed that they ...
... a deadly fish virus detected in the northeastern United States ... probably spread to at least two more. But they have ... death of hundreds of fish in Lake Ontario and the ... month, Cornell's Aquatic Animal Health Program at the College of ...
... ever done finds that the big cats reside in 40 ... ago. The tigers now occupy only 7 percent of ... commissioned by the National Fish & Wildlife Foundation's Save The ... tiger scientists at World Wildlife Fund, Wildlife Conservation Society, the ...
Cached Biology News:How HIV 'exhausts' killer T cells 2How HIV 'exhausts' killer T cells 3How HIV 'exhausts' killer T cells 4Fish virus in Northeast spreading to other fish species 2New tiger report release: Tiger habitat down from just a decade ago 2
... Mung Bean Nuclease catalyzes the degradation of ... 5-phosphoryl terminated products. While the nuclease prefers ... high concentrations the enzyme degrades double-stranded DNA ... has been used for transcript mapping studies ...
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
... is used in conjunction with ... of problematic and/or GC-rich templates ... with 10X PCRX Amplification Buffer ... magnesium concentration broader annealing temperature ...
... ZMD.473. Immunogen: Synthetic peptide derived ... mouse junctophilin-2. Specificity: Specific for ... (positive controls: mouse skeletal muscle homogenates ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store ...
Biology Products: